Evaluation of Electronic Radiotherapy Data for Quality Checking Cancer Registry Data Colin Fox (NICR) Richard Middleton (NICR) Denise Lynd (BCH – COIS)

Slides:



Advertisements
Similar presentations
High Resolution Italian studies Pamela Minicozzi Descriptive Studies and Health Planning Unit, Department of Preventive and Predictive Medicine, Fondazione.
Advertisements

Northern & Yorkshire Cancer Registry & Information Service NHS UKACR Conference 30 September How useful is the Cancer Waiting Times (CWT) dataset.
The IASLC Lung Cancer Database Summary of Cases Contributed to Project Total cases submitted 100,869 Excluded from analyses Excluded from analyses19,854.
1 Januari 2014 Via Beeld| Koptekst en voettekst kunt u deze tekst wijzigenVia Beeld| Koptekst en voettekst kunt u deze tekst wijzigen 1 Workflow of the.
Cancer of Unknown Primary Dr Chris Jones Consultant Medical Oncologist North of England Cancer Network Annual Conference 20 September 2013.
EUROCHIP PILOT STUDIES. Collection of detailed clinical information for specific tumours Describing and comparing care in representative samples of cancer.
Oncology The study of cancer. What is cancer? Any malignant growth or tumor caused by abnormal and uncontrolled cell division May be a tumor but it doesn’t.
March 2002 Outcomes in thyroid cancer: what factors are important? Information Projects Team Outcomes in thyroid cancer: what factors are important? NYCRIS.
Tumour Matching N.Ireland Experience Colin Fox (IT Manager) Richard Middleton (Data Manager)
National Cancer Registry Luxembourg EUROCHIP-3 Meeting Ispra, 27 th February 2012 Olivier Collignon, PhD, Sophie Couffignal, MD, CRP-Santé.
First HAYAT Annual Patients Forum – 21 st March 2010 – SAS, Kuwait First HAYAT Annual Patients Forum 21 st March 2010 Al Hashimi II Ballroom – SAS Hotel.
Cancer Staging. What is cancer staging? Staging describes the severity of a person’s cancer based on the extent of the original (primary) tumor and whether.
TRAM Educational Conference September 19, 2014 Meritus Medical Center 1.
NATIONAL POPULATION BASED- CANCER REGISTRY- Dr. G.Z. Mutuma Principal Research Officer, Head, Non-Communicable Diseases Research Programme, Kenya Medical.
Automated Cancer Registration N.Ireland Experience Colin Fox (IT Manager) Richard Middleton (Data Manager)
Research-driven data standards CIMI 11 th April 2013.
Waiting times for radiotherapy: variation over time and between cancer networks in southeast England David Robinson, Tom Massey & Henrik Møller Thames.
Analysis of tumour stage and treatment 26 REGISTRIES IN TOTAL –2: BREAST ONLY –2: CHILDREN ONLY DATE OF INCIDENCE RANGE: YEARS OF DATA RANGE:
Carrie Featherstone Consultant Clinical Oncologist Feb 2009.
Kenya Field Epidemiology and Laboratory Training Program (KFELTP)
Difficulties for the analysis of rare cancers Missing cases Example: angiosarcoma of liver Including false cases Example: malignant digestive endocrine.
CANCER Epidemiology Updated January 2011 Source: Cancer: New Registrations and Deaths retrieved Jan 25 th 2012 from Ministry of Health. May 2011.
1 MP/H Coding Rules General Instructions MP/H Task Force Multiple Primary Rules Histology Coding Rules 2007.
Cancer Staging.
Incidence of Childhood Cancer. What is cancer ? Uncontrolled growth of cells Are these cancer cells abnormal? No, but their behaviour is.
NATIONAL CANCER REGISTRY IRELAND. Basic registration dataset Patient dataCancer dataTreatment and follow up registration numbertumour idtreatment id year.
SPINDLE CELL SARCOMA OF BONE AN ASSESSMENT OF OUTCOME
Recurrence of Malignancy after Transplantation ANZDATA - Australian and New Zealand Dialysis and Transplant Registry NSW Cancer Council.
Statistics about unknown primary tumors Riccardo Capocaccia National Centre for Epidemiology, Surveillance and Health Promotion Istituto Superiore di Sanità,
Background  Reports of long-term survivors (≥5 years) of locally advanced esophageal cancer (LAEC) have focused mainly on HRQL or GI symptoms  Only.
Electronic Cancer Referral Dr Regina Codd GP Community Oncology Team NCCP.
HEAD/NECK OF THE SKIN ANALYTIC vs. NON-ANALYTIC by YEAR N = 1800.
Validity of more than 30Gy radiation therapy for long-surviving patients with painful bone metastases E.Katayama 1,2, H.Okada 1, I.Asakawa 2, T.Tamamoto.
Breast Cancer in Ghana How are we going to ‘beat’ it? Prof J-N Clegg-Lamptey SAMF Launch.
The treatment of metastatic squamous cell carcinoma (SCCA) of the anal canal: A single institution experience P. Pathak, B. King, A. Ohinata, P. Das, C.H.
Tools to Access the Latest Cancer Statistics Paul Miller Washington Reporting Fellowships program presentation April 15, 2013.
Cancer Outcomes and Services Dataset Linda Wintersgill Information & Audit Manager, NECN.
New Data Items MP/H Task Force Multiple Primary Rules Histology Coding Rules 2007.
National Cancer Intelligence Network data usage 17 November 2015 – Veronique Poirier – Principal Cancer Analyst – NCIN.
Cancer Services Collaborative A Service Improvement Partnership between Cancer Networks, the National Cancer Programme and the NHS Modernisation Agency.
The Royal Marsden Solitary fibrous tumours The outcomes of 106 patients illustrating the unpredictable biological behaviour N Alexander, K Thway, JM Thomas,
FRENCH high-resolution studies - Breast cancer: 1990, 1997, 2003, 2010 ? - Colorectal cancer: 1990, 1995, 2000, 2005, 2010 ? - Prostate cancer: 1995,
National Cancer Intelligence Network Outcome and the effect of age in 1318 patients with synovial sarcoma: Report from the National Cancer Intelligence.
Journal Club Dr. Eyad Al-Saeed Radiation Oncology 12 January, 2008.
Carboplatin Not Inferior to Radiation as Adjuvant Therapy for Stage I Seminoma Slideset on: Oliver RT, Mason MD, Mead GM, et al. Radiotherapy versus single-dose.
The Cancer Registry of Norway Jan F Nygård Head of the IT-department.
Sex-specific trends in lung cancer incidence and survival : a population study of cases 호흡기 내과 R3 조주희 Thorax 2011;66: Camilla M T Sagerup,
In the Name of Allah the Most Beneficent and Merciful.
Lung Cancer in Never-Smokers from the Princess Margaret Cancer Centre 1 Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada;
PD-L1 expression patterns in the metastatic tumors to the lung: a comparative study with the primary non-small cell lung cancer Zoran Gatalica1*, Jude.
UK Hospitalizations due to Stroke in Prostate Cancer Patients
CANCER CAUSES, REMEDIES & PREVENTION
Brain imaging prior to lung cancer resection
Indiana State Cancer Registry
Analysis of referral patterns and regional neuro-oncology multi-disciplinary team decisions in brain metastasis Dr Kamalram THIPPU JAYAPRAKASH, Dr Javier.
Brain imaging prior to lung cancer resection
Treatment With Continuous, Hyperfractionated, Accelerated Radiotherapy (CHART) For Non-Small Cell Lung Cancer (NSCLC): The Weston Park Hospital Experience.
Prognosis of younger patients in non-small cell lung cancer
Pathway for patients with suspected Breast Cancer
Segmented analysis of the lung cancer median pathway from referral to treatment: This work was carried out in partnership between the Transforming.
Prepared by staff in Prevention and Cancer Control.
Velindre Cancer Centre
Hannah Marder Cancer Manager UH Bristol
Estimated current cancer incidence
The Development of an E-Cancer Registry
Pathway for patients with suspected Breast Cancer
Comparing the multiple sources of cancer treatment data
THE LANCET Oncology Volume 19, No. 1, p27–39, January 2018
PICTURE HERE Eric Chokunonga Zimbabwe Cancer Registry On behalf of:
Three-year DFS rates of T x N subsets of the ACTS-CC trial and IDEA study.19 Annotation: definitions of DFS in ACTS-CC and IDEA were different. Three-year.
Presentation transcript:

Evaluation of Electronic Radiotherapy Data for Quality Checking Cancer Registry Data Colin Fox (NICR) Richard Middleton (NICR) Denise Lynd (BCH – COIS)

Clinical Oncology Information System (COIS) Radiotherapy Data – treatment intent, machine parameters, fractions, tumour site, dates. Clinical Staging Data – from year 2000 all cancers exc. NM Skins (TNM, site-specific classifications, overall stage). Chemotherapy Data – regimes, number of sessions, dates, drug details, dosages. Detailed Patient Annotation Notes. Approximately 4200 registrations annually of which around 2500 involve XRT.

Methods COIS Radiotherapy data (13,730 XRT sessions relating to approx 9400 patients). Patient and tumour data from COIS was matched to NICR Cancer Registration Database. NICR tumour data relating to site, behaviour and diagnosis date were extracted for matched COIS registrations for which no tumour match was obtained. COIS site and behaviour data as well as XRT start dates compared with corresponding NICR registration data using SPSS.

Matching Results Exact match at patient and tumour level. 12,331 XRT sessions (89.8%) 8348 registrations (89.0%) Match at patient level but not tumour XRT sessions (9.0%) 868 registrations (9.3%) Not Matched to NICR 167 XRT sessions (1.2%) 167 registrations (1.8%)

XRT Patients Not On NICR Breast37 (1% of annual incidence) NM Skin35 (0.4% of annual incidence) Prostate17 (0.8% of annual incidence) Lung16 (0.45% of annual incidence) Other Sites62 (0.35% of annual incidence) 167 cases <0.5% of annual incidence COIS registrations for selected sites that were missing from the NICR database:

No Tumour Match: Site Different NM Skin58 (0.42% of XRT cases) Site Unspecified43 (0.31% of XRT cases) Lung33 (0.24% of XRT cases) Breast24 (0.17% of XRT cases) Other Sites158 (1.15% of XRT cases) 316 (2.3% of XRT cases) Malignant sites differed between NICR and COIS in 316 XRT sessions. Number of COIS cases differing on site for selected sites:

No Tumour Match: Near Site Lung & Mesothelioma85 (0.62% of XRT cases) Head & Neck67 (0.49% of XRT cases) Colon & Rectum38 (0.28% of XRT cases) Stomach & Oesophagus34 (0.25% of XRT cases) Lymphomas27 (0.2% of XRT cases) Cervix & Uterus25 (0.18% of XRT cases) Other Sites63 (0.46% of XRT cases) 339 (2.47% of XRT cases) “Near” meaning the malignant site is similar between both NICR and COIS (339 XRT sessions). Number of COIS cases differing for selected sites:

No Tumour Match: Behaviour Differences Site Unspecified138 (1% of XRT cases) Breast133 (0.97% of XRT cases) Head & Neck 82 (0.6% of XRT cases) Lung 68 (0.5% of XRT cases) NM Skin 60 (0.44% of XRT cases) Brain 53 (0.39% of XRT cases) Other Sites 55 (0.4% of XRT cases) 589 (4.3% of XRT cases) Both NICR and COIS agree on the site but one of the sources has it as non-malignant or metastatic (589 XRT sessions). Numbers of COIS cases differing on behaviour for selected sites:

Comparison of Diagnosis and XRT Start Dates XRT began after diagnosis in majority of cases. XRT administered just before diagnosis in around 4.5% of cases, with 3% getting XRT well before NICR diagnosis date. Main sites – lung, breast, NM skin, head/neck and prostate. Reasons? Recurrent cases may account for some Metastases requiring early XRT before diagnosis of the primary tumour Possible missed pathology Requires further investigation.

Composition of NICR Tumour Registrations PASPathology COIS Deaths 2.5% 10.8% (8.7% dths) 23.6% (4.2% dths) 0.6% (<0.1% dths) 39.1% (14.9%) 18.4% (7.6%) 2.2% (1.8%) 2.7% (0.8%) (83.8%) (23.9%)

Summary and Conclusions Over 90% of COIS data matches exactly Of the 8% where tumour site differed, only 2% was significant (completely different tumour site to what was registered) Highlighted missing registrations – approx 2% over the 4 years of COIS data (0.5% per year) Helped reduce further an already low DCO rate Just over 3% of cases where radiotherapy started significantly earlier than NICR diagnosis date.

Recommendations COIS represents a clinically rich new source of electronic data for NICR and will provide for: Verification of NICR tumour registrations Enhancement of treatment data on NICR Electronic clinical staging data Follow-up on cases where: COIS tumour site differed completely to NICR and XRT start dates occurred significantly earlier than the diagnosis date on NICR Revision of system update rule for diagnosis date. Carry out a similar investigation with chemotherapy data when available.